Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases.

Abstract

EF is a rare fibrosing disorder that may involve skin and internal organs. Current therapies include moderate- to high-dose glucocorticoids with or without use of immunosuppressives. We report three cases of steroid-resistant EF in clinical practice who were treated with 3 mg/kg every 8 weeks infliximab therapy. All patients noticed an improvement in their symptoms, joint contractures and skin thickening within 8 weeks of starting infliximab therapy, ultimately leading to a drug-free remission (range 1-3 years). Based on this and other reported cases, infliximab may be beneficial in patients with steroid-resistant EF.